Holen Sie sich die Stockscreener-App
9.54
1.95%
-0.19
Handel nachbörslich:
9.54
Schlusskurs vom Vortag:
$9.73
Offen:
$9.62
24-Stunden-Volumen:
375.65K
Relative Volume:
0.48
Marktkapitalisierung:
$520.88M
Einnahmen:
$8.78M
Nettoeinkommen (Verlust:
$-104.70M
KGV:
-4.0253
EPS:
-2.37
Netto-Cashflow:
$-82.68M
1W Leistung:
+1.92%
1M Leistung:
+0.32%
6M Leistung:
-21.22%
1J Leistung:
-30.77%
1-Tages-Spanne:
$9.36
$9.70
1-Wochen-Bereich:
$9.09
$9.83
52-Wochen-Spanne:
$5.35
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
9.54 | 511.03M | 8.78M | -104.70M | -82.68M | -2.37 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Contrasting Stoke Therapeutics (NASDAQ:STOK) & Renovaro (NASDAQ:RENB) - Defense World
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference | STOK Stock News - GuruFocus
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference - Business Wire
D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Northern Trust Corp Purchases 11,635 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Chardan Capital Has Strong Forecast for STOK FY2025 Earnings - Defense World
Analysts Issue Forecasts for STOK FY2026 Earnings - Defense World
Research Analysts Issue Forecasts for STOK FY2025 Earnings - Defense World
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet - MSN
HC Wainwright Analysts Decrease Earnings Estimates for STOK - Defense World
Q2 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World
Stoke Therapeutics (NASDAQ:STOK) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Stoke Therapeutics stock target cut to $35 by H.C. Wainwright - Investing.com Canada
Price T Rowe Associates Inc. MD Purchases 2,215 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
STOK: HC Wainwright & Co. Maintains Buy Rating on Stoke Therapeu - GuruFocus
Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcoming Trial | STOK Stock News - GuruFocus
Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcomi - GuruFocus
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Stoke Therapeutics Advances with Strong Q1 2025 Results - TipRanks
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | STOK Stock News - GuruFocus
Stoke Therapeutics (STOK) Reports Significant Q1 Revenue Growth - GuruFocus
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Stoke Therapeutics Provides Business Updates - citybiz
Stoke Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Stoke Therapeutics Inc (STOK) Reports Q1 2025 Earnings: EPS of $ - GuruFocus
Stoke Therapeutics Q1 Operating Income USD 111.24 Million - marketscreener.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Gaining Ground: Stoke Therapeutics Inc (STOK) Closes Lower at 8.87, Down -1.44 - DWinneX
Wells Fargo & Company MN Has $185,000 Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Invesco Ltd. Takes Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Form DEF 14AOther definitive proxy statements - ADVFN
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Monday - Defense World
Technical analysis of Stoke Therapeutics Inc (STOK) stock chart patterns - uspostnews.com
Biogen tops estimates on rare disease strength, cuts full-year guidance - The Pharma Letter
Biogen lowers annual earnings outlook, surpasses Q1 estimates By Investing.com - Investing.com Canada
Legal & General Group Plc Decreases Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Market Momentum Report: Stoke Therapeutics Inc (STOK)’s Negative Close at 9.47 - DWinneX
Renaissance Technologies LLC Invests $1.42 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Market Highlights: Stoke Therapeutics Inc (STOK) Ends on a High Note at 9.52 - DWinneX
Stoke Therapeutics Inc (STOK) deserves deeper analysis - uspostnews.com
Geode Capital Management LLC Purchases 6,264 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? - MSN
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):